瑞慈医疗(01526.HK)中期收入11.45亿元 同比下降7.0%

Core Viewpoint - 瑞慈医疗 reported a decline in revenue and profit for the six months ending June 30, 2025, compared to the same period in 2024, indicating potential challenges in its financial performance [1] Financial Performance - The company's revenue for the six months was RMB 1,144.8 million, a decrease of 7.0% from RMB 1,231.2 million in the same period of 2024 [1] - The profit attributable to the company's owners was RMB 55.9 million, down from RMB 85.0 million in 2024 [1] - Adjusted EBITDA for the period was RMB 386.6 million, a reduction of 5.4% from RMB 408.8 million in 2024 [1] Dividend Policy - The board of directors has decided not to declare any interim dividend for the reporting period [1]